A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation

Mepolizumab, a humanized monoclonal antibody, has been developed as an add-on treatment for
subjects with severe asthma with eosinophilic inflammation. Current asthma treatment
guidelines offer minimal options for the severe asthmatic subjects on intensive therapy with
frequent exacerbations. There is a significant unmet medical need to provide better treatment
options for this segment of the asthma population. Thus, this study is designed to evaluate
the efficacy and safety of mepolizumab in Chinese severe asthmatic subjects with eosinophilic
inflammation. A total number of 300 subjects will be randomized in 1:1 ratio to receive
either mepolizumab or placebo along with existing standard of care therapy. The maximum study
duration will be 56 weeks.